ABT-263 capsule

US8927009B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Ping Tong · Potomac, US
• Deliang Zhou · Vernon Hills, US
• Geoff G. Zhang · Vernon Hills, US
• Katherine Heemstra · Chicago, US
• Cristina M. Fischer · Wadsworth, US
• Nathaniel Catron · Vernon Hills, US
• Eric A. Schmitt · Libertyville, US
• Yeshwant D. Sanzgiri · Gurnee, US

Key dates

• Filing date: Dec 21, 2010
• Grant date: Jan 6, 2015
• Expiry date: Oct 5, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.